8GN.F CESSATECH A/S DK -20

Healthcare Biotechnology Frankfurt Exchange
1.02 EUR
Close of Nov 11, 2026
0.6500 3.35
Market cap
EUR 19.0M
P/E
-
P/B
22.70x
ROE
-187.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8GN.F undervalued?

Graham number

The Graham number of CESSATECH A/S DK -20 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CESSATECH A/S DK -20 fundamental analysis

No fundamental analysis for CESSATECH A/S DK -20 yet.

CESSATECH A/S DK -20 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CESSATECH A/S DK -20

Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of…

Full company profile